RAPT Therapeutics, Inc.
8 clinical trials · Sponsor
◉ Watch RAPT Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy (NCT07220811) | RAPT Therapeutics, Inc. | 2025-10-22 |
| Study of RPT193 in Healthy Adult Male Subjects (NCT06087978) | RAPT Therapeutics, Inc. | 2023-07-05 |
| Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma (NCT05935332) | RAPT Therapeutics, Inc. | 2023-07-05 |
| An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis (NCT05399368) | RAPT Therapeutics, Inc. | 2022-06-07 |
| A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis (NCT04271514) | RAPT Therapeutics, Inc. | 2019-08-12 |
| Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab (NCT03674567) | RAPT Therapeutics, Inc. | 2018-09-25 |
Track RAPT Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.